JP2020510827A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510827A5 JP2020510827A5 JP2019546343A JP2019546343A JP2020510827A5 JP 2020510827 A5 JP2020510827 A5 JP 2020510827A5 JP 2019546343 A JP2019546343 A JP 2019546343A JP 2019546343 A JP2019546343 A JP 2019546343A JP 2020510827 A5 JP2020510827 A5 JP 2020510827A5
- Authority
- JP
- Japan
- Prior art keywords
- rodent
- gene
- symptoms
- locus
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464262P | 2017-02-27 | 2017-02-27 | |
| US62/464,262 | 2017-02-27 | ||
| US201762529916P | 2017-07-07 | 2017-07-07 | |
| US62/529,916 | 2017-07-07 | ||
| US201762583780P | 2017-11-09 | 2017-11-09 | |
| US62/583,780 | 2017-11-09 | ||
| PCT/US2018/019651 WO2018157027A1 (en) | 2017-02-27 | 2018-02-26 | Humanized model of kidney and liver disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510827A JP2020510827A (ja) | 2020-04-09 |
| JP2020510827A5 true JP2020510827A5 (https=) | 2021-04-01 |
| JP7169979B2 JP7169979B2 (ja) | 2022-11-11 |
Family
ID=61617150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546343A Active JP7169979B2 (ja) | 2017-02-27 | 2018-02-26 | 補体関連腎症および肝線維症の候補治療剤の治療有効性を評価する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10765762B2 (https=) |
| EP (1) | EP3585445B1 (https=) |
| JP (1) | JP7169979B2 (https=) |
| KR (1) | KR102602199B1 (https=) |
| CN (1) | CN110494168B (https=) |
| AU (1) | AU2018225745B2 (https=) |
| CA (1) | CA3054167A1 (https=) |
| ES (1) | ES2975416T3 (https=) |
| IL (1) | IL268748B2 (https=) |
| MX (1) | MX2019010219A (https=) |
| SG (2) | SG10202111663PA (https=) |
| WO (1) | WO2018157027A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX394999B (es) | 2017-09-29 | 2025-03-24 | Regeneron Pharma | Animales no humanos que comprenden un locus ttr humanizado y metodos de uso |
| IL278267B2 (en) | 2018-07-16 | 2025-02-01 | Regeneron Pharma | Non-human animal models of DITRA disease and their uses |
| JP7222075B2 (ja) * | 2018-09-13 | 2023-02-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃ３糸球体症のモデルとしての補体因子ｈ遺伝子ノックアウトラット |
| ES2966625T3 (es) | 2019-04-04 | 2024-04-23 | Regeneron Pharma | Roedores que comprenden un locus del factor de coagulación 12 humanizado |
| US11891618B2 (en) | 2019-06-04 | 2024-02-06 | Regeneron Pharmaceuticals, Inc. | Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use |
| US11622547B2 (en) | 2019-06-07 | 2023-04-11 | Regeneran Pharmaceuticals, Inc. | Genetically modified mouse that expresses human albumin |
| WO2021112235A1 (ja) * | 2019-12-05 | 2021-06-10 | 国立大学法人宮崎大学 | Ｃ３腎症を予防又は治療するための医薬、医薬組成物及び補体Ｃ３ｂ分解促進剤 |
| AU2021352420A1 (en) | 2020-10-01 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Rodent animals expressing human cr1 |
| WO2025122669A1 (en) | 2023-12-05 | 2025-06-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized complement factor b gene |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984003506A1 (en) | 1983-03-08 | 1984-09-13 | Commw Serum Lab Commission | Antigenically active amino acid sequences |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4708871A (en) | 1983-03-08 | 1987-11-24 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| GB2183661B (en) | 1985-03-30 | 1989-06-28 | Marc Ballivet | Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique |
| NZ215865A (en) | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| US5266684A (en) | 1988-05-02 | 1993-11-30 | The Reagents Of The University Of California | Peptide mixtures |
| US5571689A (en) | 1988-06-16 | 1996-11-05 | Washington University | Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid |
| US5663143A (en) | 1988-09-02 | 1997-09-02 | Dyax Corp. | Engineered human-derived kunitz domains that inhibit human neutrophil elastase |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
| US5770434A (en) | 1990-09-28 | 1998-06-23 | Ixsys Incorporated | Soluble peptides having constrained, secondary conformation in solution and method of making same |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009300A1 (en) | 1990-11-21 | 1992-06-11 | Iterex Pharmaceuticals Ltd. Partnership | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
| US5644048A (en) | 1992-01-10 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Process for preparing phosphorothioate oligonucleotides |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| GB9521943D0 (en) | 1995-10-26 | 1996-01-03 | Univ Hertfordshire | Coded particles for process sequence tracking in combinatorial compound library preparation |
| ES2292236T3 (es) | 1998-04-02 | 2008-03-01 | Genentech, Inc. | Variantes de anticuerpos y sus fragmentos. |
| US6335155B1 (en) | 1998-06-26 | 2002-01-01 | Sunesis Pharmaceuticals, Inc. | Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules |
| US6280946B2 (en) | 1998-08-07 | 2001-08-28 | Boston Probes, Inc. | PNA probes, probe sets, methods and kits pertaining to the universal detection of bacteria and eucarya |
| CA2355215A1 (en) | 1998-12-28 | 2000-07-06 | Jim Wells | Identifying small organic molecule ligands for binding |
| US20090032592A1 (en) | 2006-01-11 | 2009-02-05 | Novo Nordisk A/S | Spherical encoded beads |
| BRPI0812767A2 (pt) * | 2007-06-07 | 2014-12-02 | Genentech Inc | Anticorpos para c3b e métodos para prevenção e tratamento de distúrbios associados ao complemento |
| LT2894165T (lt) | 2008-11-10 | 2023-03-10 | Alexion Pharmaceuticals, Inc. | Būdai ir kompozicijos, skirti su komplementu susijusių sutrikimų gydymui |
| US9243060B2 (en) * | 2012-04-03 | 2016-01-26 | Novelmed Therapeutics, Inc. | Humanized anti-factor C3b antibodies and uses thereof |
| WO2014002054A1 (en) * | 2012-06-28 | 2014-01-03 | Novartis Ag | Pyrrolidine derivatives and their use as complement pathway modulators |
| AU2014306002B2 (en) * | 2013-08-07 | 2017-05-25 | Alexion Pharmaceuticals, Inc. | Atypical hemolytic uremic syndrome (aHUS) biomarker proteins |
| US9659904B2 (en) * | 2013-12-12 | 2017-05-23 | Intel Corporation | Distributed on-package millimeter-wave radio |
| HRP20200182T1 (hr) * | 2014-02-25 | 2020-05-01 | Achillion Pharmaceuticals, Inc. | Aril, heteroaril i heterociklični spojevi za liječenje komplementom posredovanih poremećaja |
| SG10202003996YA (en) * | 2014-05-05 | 2020-06-29 | Regeneron Pharma | Humanized c5 and c3 animals |
-
2018
- 2018-02-26 US US15/904,808 patent/US10765762B2/en active Active
- 2018-02-26 MX MX2019010219A patent/MX2019010219A/es unknown
- 2018-02-26 JP JP2019546343A patent/JP7169979B2/ja active Active
- 2018-02-26 ES ES18710242T patent/ES2975416T3/es active Active
- 2018-02-26 WO PCT/US2018/019651 patent/WO2018157027A1/en not_active Ceased
- 2018-02-26 CN CN201880021486.3A patent/CN110494168B/zh active Active
- 2018-02-26 CA CA3054167A patent/CA3054167A1/en active Pending
- 2018-02-26 EP EP18710242.1A patent/EP3585445B1/en active Active
- 2018-02-26 AU AU2018225745A patent/AU2018225745B2/en active Active
- 2018-02-26 SG SG10202111663PA patent/SG10202111663PA/en unknown
- 2018-02-26 SG SG11201907606XA patent/SG11201907606XA/en unknown
- 2018-02-26 KR KR1020197027971A patent/KR102602199B1/ko active Active
- 2018-02-26 IL IL268748A patent/IL268748B2/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020510827A5 (https=) | ||
| Faget et al. | Unmasking senescence: context-dependent effects of SASP in cancer | |
| Li et al. | Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure | |
| Chen et al. | Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice | |
| Bracey et al. | The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin‐1β | |
| Vo et al. | Modifier genes and their effect on Duchenne muscular dystrophy | |
| Rajapaksha et al. | Liver‐targeted angiotensin converting enzyme 2 therapy inhibits chronic biliary fibrosis in multiple drug‐resistant gene 2‐knockout mice | |
| Bongoni et al. | Overexpression of human CD55 and CD59 or treatment with human CD55 protects against renal ischemia-reperfusion injury in mice | |
| Yuen et al. | Recombinant N–terminal Slit2 inhibits TGF-β–induced fibroblast activation and renal fibrosis | |
| JP7169979B2 (ja) | 補体関連腎症および肝線維症の候補治療剤の治療有効性を評価する方法 | |
| Chen et al. | Metformin attenuates angiotensin II‐induced TGFβ1 expression by targeting hepatocyte nuclear factor‐4‐α | |
| Dahiya et al. | Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy | |
| JP2021513993A (ja) | 血管疾患を処置するための方法および組成物 | |
| Jensen et al. | Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications | |
| RU2010136040A (ru) | Композиции, способные синергично вызывать посттранскрипционный сайленсинг экспрессии генов, и способы их применения | |
| Imai et al. | Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload | |
| Chen et al. | AKT2 deficiency induces retardation of myocyte development through EndoG-MEF2A signaling in mouse heart | |
| Wang et al. | Potential application of modified mRNA in cardiac regeneration | |
| Dreieicher et al. | Nitric oxide inhibits glomerular TGF-β signaling via SMOC-1 | |
| JP5584618B2 (ja) | 慢性疼痛の治療又は予防のためのグラニュリン又はグラニュリン様化合物の使用 | |
| Jiang et al. | Establishment of basal cell carcinoma animal model in Chinese tree shrew (Tupaia belangeri chinensis) | |
| Araújo et al. | Dual-acting antiangiogenic gene therapy reduces inflammation and regresses neovascularization in diabetic mouse retina | |
| US10456398B2 (en) | Inhibition of SGK1 in the treatment of heart conditions | |
| Borza et al. | Genetic and pharmacological tools to study the role of discoidin domain receptors in kidney disease | |
| CN112353940A (zh) | 一种用于预防或治疗抑郁症的药物及其应用 |